Medgenics Share Discussion Threads

[jammytass] 19/6/2012 20:40

get ready for lift off !!!! £7.00 end of july £10+ = year end

MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Jun. 19, 2012-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of a novel Biopump™ technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced it has raised gross proceeds of approximately $9.5 million (approximately $8.4 million net) through the sale of 1,944,734 units (the "Units"), with each Unit consisting of one share of the Company's Common Stock, $0.0001 par value per share (the "Common Stock"), and a warrant to purchase 0.75 of one share of Common Stock (the "Warrants"). Each Unit was sold for a purchase price of $4.90 to institutional and other accredited investors in a private placement transaction. The Warrants expire in five years, have an initial exercise price of $8.34 per full share and become first exercisable on December 15, 2012.

Medgenics intends to use the proceeds from this private placement to further its clinical trial programs for its EPODURE™ Biopump producing erythropoietin for the treatment of anemia, and its INFRADURE™ Biopump producing interferon-alpha for the treatment of hepatitis, as well as for other research and development, patent maintenance and other intellectual property support and general corporate purposes.

The Units, including the Common Stock and the Warrants constituting the Units, and the shares of Common Stock issuable upon the exercise of the Warrants have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold absent registration or an applicable exemption from registration. Medgenics has agreed to cause the resale of the Common Stock issued as part of the Units and the shares of Common Stock issuable upon the exercise of the Warrants to be registered for resale with the U.S. Securities and Exchange Commission.

Maxim Group LLC acted as the exclusive placement agent for the private placement.

[pdt] 19/6/2012 18:41

Or with the uncertainty over funding removed the shares can push ahead to £6.

I would certainly buy more if the price falls but I have a feeling any pull back will be short lived.

[sicilian_kan] 19/6/2012 15:57

And there we go. A large placing done at £3.12p, with yet more warrants in addition. No surprises here. Looks like share price has a lot further to fall. Once the placing price is hit, I will consider buying again.

[jammytass] 07/6/2012 15:34

Medgenics Initiates U.S. Biopump Processing Site

Facility initially to supply EPODURE for U.S. anemia clinical trials

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), ("the Company") the developer of the novel Biopump™ technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announced today it has initiated its first U.S. Biopump processing facility in Davis, California.



EPODURE™ Biopumps for the treatment of anemia are now being processed by the Company's contract manufacturing organization ("CMO") in a good manufacturing practice ("GMP") certified facility. This marks the first Biopump processing site outside of Israel, and provides Medgenics with a significant ability to scale-up its clinical and commercial capabilities to address global therapeutic areas such as anemia and hemophilia.

[count chris] 30/5/2012 22:00

Would be great to see it close above £4:00 tomorrow.

[sicilian_kan] 30/5/2012 08:26

Market cap now £40.3m, or £67.3m if fully diluted (i.e. warrants etc exercised).

[andrbea] 30/5/2012 08:20

2% up

29/05/2012 16:37:59 MEDU 388.00 O 5,000
29/05/2012 16:32:04 MEDU 395.00 O 4,500

[count chris] 25/5/2012 21:12

Can you back that up or just hoping?

[jammytass] 25/5/2012 17:57

deal looks on the cards sharp rise very soon!!!

[sicilian_kan] 14/5/2012 22:03

Looks like they needed that grant. 1st quarter results out today.

Cash on 31 March 12 - $2.6m
Cash on 31 Dec 11 - $5.0m

Cash burn therefore $2.4m for the Quarter. Was due to run out of cash at the end of June. Is now going to run out of cash in Q3, i.e. in 4 months time, assuming all the £2.2m is paid up front, which it is unlikely to be (RNS states up to $2.2m net).

There is a severe need for a placing or for a deal.

[jammytass] 09/5/2012 17:47

Medgenics Awarded $2.2 Million Grant from the Israeli Office of the Chief Scientist
MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May. 9, 2012-- Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI) was awarded a government grant of up to NIS 8.1 million (approximately USD 2.2 million), net, from the Office of the Chief Scientist ("OCS") at the Ministry of Industry, Trade and Labor of Israel.

The grant will be used to cover R&D expenses for the 12-month period from October 2011 through September 2012 to support further research and clinical development of the Company's proprietary tissue-based Biopump™ platform technology in a number of indications including anemia and hepatitis.

The OCS awards grants to companies from various industries in Israel to foster technological innovations. Recipient selections are based on multiple criteria including the uniqueness of a company's technology, and the potential market it addresses, plus the robustness of the company's business including financial position, R&D capabilities and management experience.

Under the terms of the OCS grant, MMI will repay the grant in full, plus interest, through royalties on revenue received from commercializing the developed technology. The payment of royalties is contingent on such revenues and, in the absence of such revenues, no royalty payments to the OCS are required.

"This marks our sixth consecutive year of being selected to receive non-dilutive funding from the Israeli OCS. We are grateful for this support, which underscores their ongoing belief in the potential of our innovative Biopump platform technology. Prior grants have helped to fund the development of our technology to a point where we are now working to commence clinical trials for the treatment of anemia and hepatitis in the United States and Israel. We anticipate this grant will further advance our product development and will help us to achieve a number of important milestones

[sicilian_kan] 26/4/2012 18:56

I make the current market cap undiluted £39m and fully diluted (warrants and options exercised) as £66m (assuming 70% are MGDN and 30% are AIM).

[jammytass] 26/4/2012 16:06

well a deal would be perfect> up 19% in usa today thats 42% in 2 days







4

[sicilian_kan] 25/4/2012 22:47

PDT that is the key, I agree with you. Funding is now required.

The Finals state that "As of December 31, 2011 Medgenics had $5.00 million in cash and cash equivalents". There is an operating loss of $10m / year and a loss of $8m/yr. Let's take the latter figure. Medgenics have enough cash until August. Funds therefore must be raised in April / May.

There will in my opinion either be an imminent placing or a deal. My hunch is a placing but I have an open mind. I think this as:

1. the CEO shamelessly ramped the price up earlier this year speaking to the blonde. Unnecessary if a deal was in place.

2. companies negotiate the best deals when funded to avoid being forced into weak deals, unless there is competition in terms of bids.

3. Baxter, the most likely of the candidates, have not renewed their Agreement with Medgenics or exercised the exclusivity option. If there were multiple parties interested (in Hemodure or Medgenics as a whole) including them, then they would have exercised this exclusivity period. There are no encouraging words in the finals to suggest that there is further contact. Of course it may be that the deal is for something Baxter is not interested in.

Now I may be wrong, and good luck to people here and I hope I am wrong. I will be the first to be happy for you guys as there is SO much potential in this company. But there are too many uncertainties for me to be in at present. Lack of deals, possibility of dilution and YET more warrants, Baxter appears dead, ramping by CEO, EU patent granted but watered down (I do not understand what they have lost precisely and how strong the patents now are in Europe) etc. Just too much uncertainty. But this COULD be the next $bn pharma too. I'm out on the sidelines. If the placing happens and is not too bad AND if Blech maintains or increases his stake, then I am back in. If Blech does not maintain his stake, I am permanently out.

[pdt] 25/4/2012 22:18

jammytass

I agree with you. I would buy more but I'm starting to worry that their funding is running out. A partner deal would change that and give a massive vote of confidence in the technology.

Paul

[jammytass] 25/4/2012 18:34

nice find, a partner deal would double the share price !!!

[pdt] 25/4/2012 18:30

Take a look at this article;



Up 20% at the moment in the US today.

[jammytass] 25/4/2012 16:55

major deal on the cards> factory/tie inn watch for large rises in the usa

[bikkit] 25/4/2012 15:48

Anyone know whats happening with this one, been recommended by broker but rns not saying too much

[jammytass] 19/4/2012 06:02

up 17% in usa